Roche’s Japan-based subsidiary, Chugai Pharmaceutical, has filed a new patent infringement suit against Alexion in the District Court of Delaware.
Drug maker Alexion has been seeing success with its strategy to defend against biosimilars, a plan that largely relies on transitioning patients with rare disease successfully treated with eculizumab (Soliris) to a longer-acting C5 inhibitor, ravulizumab (Ultomiris), before eculizumab faces oncoming biosimilar competition from products currently in phase 3 development.
According to Alexion’s third quarter financial results, approximately 51% of patients with paroxysmal nocturnal hemoglobinuria who were taking eculizumab have now been switched to ravulizumab, and an approval in atypical hemolytic uremic syndrome will see additional patients switch in the days ahead. The drug maker is also pursuing phase 3 clinical programs for the long-acting product in myasthenia gravis, as well as a subcutaneous version of the drug in multiple indications.
However, trouble may be ahead for Alexion; this month, Roche’s Japan-based subsidiary, Chugai Pharmaceutical, filed a patent infringement suit against Alexion in the District Court of Delaware.
The complaint alleges that ravulizumab infringes on Chugai’s technology that extends the half-life of an antibody in blood plasma, improving the length of time for which the antibody can bind to and neutralize an antigen. Chugai’s patent relates to a method of removing an antigen from blood plasma using antibodies with long half-lives in plasma, allowing antibodies to have longer durations of time during which they can bind to antigens.
According to the complaint, Chugai is developing “numerous medicines, including a C5 inhibitor,” that will use this proprietary approach and says that ravulizumab incorporates Chugai’s patented technology.
Furthermore, Chugai claims that Alexion tried to stop Chugai from obtaining the patent that is the subject of the complaint. Chugai says that an attorney—who did not at that time identify herself as working for Alexion—filed a third-party submission intended to keep the patent from issuing.
Chugai has asked for injunctive relief to prevent ravulizumab from being manufactured, used, or sold.
Another action brought by Chugai is also pending before the same court. That action is also related to proprietary antibody engineering technology, and Chugai seeks a judgement that ravulizumab infringes on Chugai’s US patents and asks the court to block US sales of the product.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.